Bioceltix, a Wrocław-based stem cell company, has submitted responses to regulatory questions from the European Medicines Agency (EMA) regarding its lead therapeutic candidate BCX-CM-J for canine osteoarthritis. This represents a key milestone in the drug registration process ahead of market approval.
Commerzbank formally rejected UniCredit’s takeover bid valued at €39 billion, claiming it undervalues the bank by 5.6% and carries significant risks. The board recommended shareholders reject the stock exchange proposal, citing vague integration plans and unrealistic synergy estimates. Commerzbank is promoting its independent ‘Momentum 2030’ strategy instead.
A new analysis by The Association of Listed Danish Companies (FBV) reveals 54 Danish companies with IPO potential by 2030, including scaled startups like Pleo, Lunar, Veo, and Too Good To Go. The report suggests Denmark’s IPO pipeline is stronger than commonly assumed, with these 54 candidates representing nearly a third of the current Danish stock market. The analysis recommends three key steps: encouraging pension fund investment in Danish equities, improving retail investor incentives, and simplifying the listing process.
Destinus, a Dutch defence tech startup founded in 2021, is in talks to raise approximately €200m in a pre-IPO funding round, seeking a valuation above €5bn based on forecast annual revenues of €500m. The company, which develops drones and cruise missiles, recently acquired Swiss autonomous pilot startup Daedalean for $225m to strengthen its AI and autonomous flight capabilities.
Czech-led Exaforce raised over €100 million in funding
Anthropic is raising $30 billion at a $900 billion valuation, surpassing OpenAI. The round is led by Dragoneer, Greenoaks, Sequoia Capital, and Altimeter Capital, each investing at least $2 billion. This comes three months after a previous $30 billion round at $350 billion valuation. Anthropic’s revenue is projected to reach $45 billion this year, five times higher than last year’s $9 billion, driven by the success of Claude and its new capabilities like Claude Cowork. The company continues to face scrutiny from European regulators regarding access to its latest Claude Mythos model.